Jardimet XR Tablet 25 mg + 1000 mg is an extended-release fixed-dose combination of Empagliflozin and Metformin Hydrochloride, formulated for the long-term management of type 2 diabetes mellitus in adults. This advanced combination therapy is designed for patients who require higher doses of metformin along with an SGLT2 inhibitor to achieve optimal glycemic control while maintaining dosing convenience and improved gastrointestinal tolerability.

Metformin Hydrochloride, a biguanide, reduces hepatic glucose production, improves insulin sensitivity, and decreases intestinal glucose absorption. Empagliflozin, a Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor, lowers blood glucose by promoting urinary excretion of excess glucose. The extended-release (XR) formulation of metformin allows gradual drug release, helping maintain steady blood levels and reducing common gastrointestinal side effects associated with immediate-release metformin.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each extended-release tablet contains:

• Empagliflozin 25 mg

• Metformin Hydrochloride 1000 mg (Extended Release)

Therapeutic Class

• Antidiabetic Agents

• SGLT2 Inhibitor + Biguanide (Extended-Release Combination)

Indications and Uses

Jardimet XR Tablet 25 mg + 1000 mg is indicated for:

• Management of type 2 diabetes mellitus in adult patients

• Patients inadequately controlled on metformin or combination therapy

• Adjunct to diet and lifestyle modifications to improve glycemic control

• Long-term diabetes management requiring once-daily high-dose metformin

Mechanism of Action

Metformin XR lowers blood glucose by decreasing hepatic gluconeogenesis, improving peripheral insulin sensitivity, and reducing glucose absorption from the intestine. Empagliflozin inhibits the SGLT2 transporter in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. Together, they provide complementary and insulin-independent glucose-lowering effects.

Key Benefits

• Dual-mechanism approach for effective blood glucose control

• Extended-release metformin improves gastrointestinal tolerability

• Once-daily dosing enhances patient compliance

• Low risk of hypoglycemia when used without insulin or sulfonylureas

• Supports weight control and metabolic balance

Dosage and Administration

• Taken orally once daily, preferably with food

• Tablets should be swallowed whole; do not crush or chew

• Dosage is individualized based on glycemic response and renal function

• Regular monitoring of blood glucose and kidney parameters is essential

Precautions and Warnings

• Not indicated for type 1 diabetes or diabetic ketoacidosis

• Use cautiously in patients with renal or hepatic impairment

• Risk of dehydration; maintain adequate fluid intake

• Rare risk of lactic acidosis associated with metformin

• Avoid excessive alcohol consumption during treatment

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

Common side effects may include gastrointestinal discomfort, diarrhea, nausea, increased urination, urinary tract infections, and genital fungal infections. Most reactions are mild to moderate and tend to decrease with continued therapy.

Storage Conditions

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

Conclusion

Jardimet XR Tablet 25 mg + 1000 mg (Empagliflozin + Metformin Hydrochloride) offers a convenient and effective once-daily treatment option for adults with type 2 diabetes mellitus requiring combination therapy. Its extended-release formulation, combined with dual glucose-lowering mechanisms, supports sustained glycemic control and improved treatment adherence under medical supervision.